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Abstract
The aim. To study the cerebroprotective activity of a new derivative of 4-aminobutanoic acid the compound KGM-5 
on the effect on survival and behavioural responses, cognitive impairment and neurological deficits in rats with acute cerebrovas-
cular accident.
Materials and methods. Acute cerebrovascular accident (ACVA) was simulated in rats by irreversible unilateral carotid 
occlusion (UCO) under anesthesia with sodium thiopental (35 mg/kg, intraperitoneally, IP). Five groups of animals were used: intact 
control (IC, n = 6), a group of animals with ACVA, which were not treated (control pathology, CP, n = 13); group of animals with 
ACVA, which were treated for 5 days after surgery (first injection 30 min before surgery) with the compound KGM-5 (ACVA+KGM-5, 
n = 14) at a conditionally effective dose of 30 mg/kg body weight of animals, a group of animals with ACVA (ACVA+CD «Picamilon», 
n = 13), who received IP for 5 days, the comparison drug (CD) «Picamilon» at a dose of 17 mg/kg and pseudo-operated animals (POA), 
n = 8), which were operated without ligation of the carotid artery, which allows to level the effect of anesthesia and surgery on the 
studied indicators. The cerebroprotective effect of the studied agents was assessed by an integral criterion – survival of animals 
(throughout the experiment), indicators of neurological deficit (24, 48, 72, 94 hours after ACVA modelling), the state of cognitive 
functions in the test of extrapolation escape test (EET) (72 hours after ACVA modelling)
Results. The KGM-5 compound contributed to a significant reduction in the severity of neurological deficit, as evidenced 
by significant differences in this indicator compared with CP, respectively, the first (0.5 points vs. 1.25 points, p < 0.05), the 
third (0.0 points against 1.0 point, p < 0.05) and the fourth day (0.0 points vs. 0.5 points, p < 0.05) after OCO. Under the influence 
of CD «Picamilon» reduction of neurological deficit compared with CP was observed on the first, third and fourth days, but these 
differences were insignificant (p > 0.05). Both studied agents – the compound KGM-5 and CD «Picamilon» contributed to the im-
provement of cognitive functions of rats with ACVA, as evidenced by a significant reduction (p < 0.05) of the latent period of diving 
in the EET, respectively, 1.8 and 1.7 times compared with CP and did not show a significant effect on animal survival.
Conclusion. The cerebroprotective activity of a new 4-aminobutanoic acid derivative in the conditions of acute cerebrovas-
cular accident in rats was established in terms of the ability to reduce the severity of neurological deficits and improve cognitive func-
tions in the extrapolation escape test. The severity of cerebroprotective activity of the new compound is not inferior to GABA-ergic 
drug «Picamilon».
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1. Introduction
Cognitive disorders are one of the most important medical and social problems of modern 
society. There are about 50 million people in the world who suffer from various forms of dementia. 
The number of patients with severe cognitive impairments doubles every ten years, and by 2050 
the total number of patients on Earth with this disease will reach 130 million [1, 2]. The main 
diseases of the brain that contribute to the development of cognitive dysfunction are neurodegene-
rative (Alzheimer’s disease, etc.), vascular (cerebral ischemia), traumatic brain injury, neuroinfec-
tions and others [1, 3, 4]. Cerebrovascular disorders are the second most common cause of dementia 
after Alzheimer’s disease. Vascular dementia occupies from 10 to 30 % in the overall structure of 
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dementia [1, 4, 5]. Vascular disorders lead to changes in cerebral blood flow with the development 
of hypoxia of brain tissues, disruption of nutrition and energy supply of neurons, which contributes 
to the development of intracellular biochemical changes and diffuse multifocal brain damage. The 
latter leads to the development of cognitive disorders [6–8]. For the treatment of cognitive disorders 
in complex therapy are widely used cerebroprotectors, nootropics, which are not always effective 
and safe [9–12]. In this regard, the search for new nootropic drugs that can improve cognitive im-
pairment resulting from acute or chronic cerebral circulatory disorders is an urgent scientific task. 
Promising in this regard are new derivatives of 4-aminobutanoic acid, synthesized at the National 
University of Pharmacy, among 11 of which was selected the leading substance for antiamnestic ac-
tivity under the conditional name KGM-5, which also exhibits antihypoxic activity [13]. Given the 
above, it is advisable to study its ability to improve cognitive impairment and neurological deficits 
resulting from acute cerebrovascular accident.
The aim. To study the cerebroprotective activity of a new derivative of 4-aminobutanoic 
acid, the compound KGM-5, on the effect on survival and behavioural responses, cognitive impair-
ment and neurological deficits in rats with acute cerebrovascular accident. 
2. Materials and methods
In the experiment, white adult non-linear male rats weighing 200 ± 20 g were used [14]. Rats 
were divided into groups that were formed by randomization using body weight as the main fea-
ture. The research was conducted on the basis of the Educational and Scientific Training Center for 
Medical and Biological Research of the Educational and Scientific Institute of Applied Pharmacy 
of the National University of Pharmacy (NUPh) in the spring of 2020, natural light regime «day and 
night», in standard cages, on a standard diet. 
All manipulations with animals were carried out in accordance with GLP requirements, 
recommendations of the State Expert Center of the Ministry of Health, General Ethical Principles 
of Animal Experiments (Ukraine, 2001), Law of Ukraine of February 21, 2006 No. 3447-IV as 
amended «On the protection of animals from cruel treatment», the decision of the First National 
Congress on Bioethics (Kyiv, 2007) and the European Convention for the Protection of Vertebrate 
Animals Used for Experimental or Other Scientific Purposes [15].
Гостре порушення мозкового кровообігу (ACVA) моделювали у щурів шляхом 
незворотної односторонньої каротидної оклюзії (UCO) [16]. To reproduce the ACVA model, 
the animals were anesthetized with sodium thiopental (35 mg/kg, ip), fixed in the supine position, 
the hair on the neck was removed, and the soft tissues of the neck were dissected by blunt cutting 
off the fascia. The left common carotid artery was isolated, connective tissue and nerve trunks 
were separated around it, ligatures were brought under the vessel and it was ligated. The wound 
was sutured in layers and treated with antiseptic (0.05 % solution of chlorhexidine bigluconate). All 
the above manipulations were performed with pseudo-operated animals (POA, n = 8), except for 
ligation of the carotid artery, which allows to neutralize the effect of anesthesia and surgery on the 
studied parameters. A total of 5 groups of animals were used: intact control (IC, n = 6), a group of 
animals with ACVA, which were not treated (control pathology, CP, n = 13); group of animals with 
ACVA, which were treated for 5 days after surgery (first administration 30 min after surgery) with 
the KGM-5 compound (ACVA+KGM-5, n = 14) at a conditionally effective dose of 30 mg/kg of body 
weight of animals [13] and a group of animals with ACVA (ACVA+CD «Picamilon», n = 13), who 
received ip for 5 days the comparison drug (CD) «Picamilon» (solution for injection 100 mg/ml, 
manufactured by JSC «Pharmstandard UfaVITA», Russia) at a dose of 17 mg/kg, which was calcu-
lated from the daily dose for humans (200 mg/day) using the coefficient of species sensitivity [17]. 
The cerebroprotective effect of the studied agents was assessed by an integral criterion – survival 
of animals (throughout the experiment), indicators of neurological deficit (24, 48, 72, 94 hours after 
ACVA modelling) [17], the state of cognitive functions in extrapolation escape test (EET) (through 
72 hours after ACVA modelling) [17]. Neurological deficiency in animals was determined by the 
McGraw Stroke-Index Scale in the modification of Gannushkina I. V. [17]. The severity of the 
condition was determined by the sum of points: up to 3 points – mild, 3–7 – moderate, 7 points 
and above – severe. Animals were tested daily, counting scores. Paresis, paralysis of the extremities, 
Original Research Article:
full paper
(2021), «EUREKA: Health Sciences»
Number 3
97
Pharmacology, Toxicology and Pharmaceutical Science
tremor, circling behavior, ptosis, lateral position on the side, mobility of animals were noted. 
Evaluation of the cognitive functions of rats with ACVA was performed in the extrapolation release 
test [17]. The device for this test is a cylinder made of transparent acrylic plastic, which is installed 
in a vessel of cylindrical shape of larger diameter and height to fill it with water. A special metal 
mount holds the cylinder in the center of this tank. During the test, the ability of the animal, pre-
viously placed in the inner cylinder, to find a way out of it by diving under its submerged lower 
edge into the water, as well as the percentage of rats that coped with the task within 3 minutes were 
observed. For testing, the unit was filled with water at a temperature of 20–25 °C so that the inner 
cylinder was immersed in water by 2.5 cm. The rats were placed in a clear plastic cylinder 40 mi-
nutes after the introduction of KGM-5 or CD. 
The obtained data were expressed as the mean and its standard error. Comparison of data 
samples after evaluation of the nature of the distribution was performed using ANOVA analysis of 
variance and Newman-Keils test (for parametric data) or Kruskal-Wallis method and Mann-Whitney 
test (for non-parametric data). Differences between groups were considered statistically significant 
at p < 0.05. Statistica 6 and Excel software packages were used for statistical data processing [18].
3. Results
Analysis of the survival of animals with ACVA shows that the maximum death of animals 
occurred at 24 h after UCO (Table 1). 
Table 1
The effect of KGM-5 and CD «Picamilon» on the survival rates of rats with the ACVA model
Group n
Survival of animals (number/%) on
24 h 48 h 72 h 96 h
Intact control (IC) 6 6/100 6/100 6/100 6/100
Pseudo-operated animals (POA) 8 8/100 8/100 8/100 8/100
Control pathology (CP) 13 8/61.5*# 8/61.5*# 8/61.5*# 8/61.5*#
ACVA+KGM-5 (30 mg/kg, ip) 14 12/85.7# 12/85.7# 12/85.7# 12/85.7#
ACVA+CD «Picamilon» (30 mg/kg, ip) 13 10/76.9*# 10/76.9*# 10/76.9*# 10/76.9*#
Note: * – differences are significant versus intact control, p < 0.05 (Fisher test); # – differences are significant versus pseudo- 
operated animals, p < 0.05 (Fisher test); n – number of animals
The POA group had 100 % survival. In the CP 8 group of 13 animals survived, i.e. survival 
was 61.5 %, which was significantly lower compared to IC and POA. Under the influence of KGM-5, 
the survival of the animals was significantly lower compared to POA and was 85.7 % (12 of 14) 
for 24 hours of the experiment and was so for 4 days of the experiment. Under the influence of 
CD «Picamilon», the survival rate of rats with ACVA was 76.9 %, which was significantly lower 
compared to IC and POA (p < 0.05 according to Fisher’s test).
Cerebral ischemia is a complex of neurological symptoms.
General inhibition and decreased muscle tone, tremor, ptosis, circling behavior, paresis and 
paralysis of the extremities were particularly pronounced. Neurological deficit according to the 
McGraw Stroke-Index Scale in untreated animals (CP group) was expressed during the first three 
days with a maximum on the first day after UCO (Table 2), as evidenced by the probable differenc-
es of this indicator compared with IC. 
In general, the results correspond to the literature [9]. The absence of neurological disor-
ders (except for mild symptoms in the first 24 hours) in the POA group confirms the adequacy 
of the model reproduction technique and its specificity. The KGM-5 compound contributed to 
a significant reduction in the severity of neurological deficit, as evidenced by significant differen-
ces in this indicator compared with CP, respectively, the first (0.5 points vs. 1.25 points, p < 0.05), 
the third (0.0 points vs. 1.0 point, p < 0.05) and the fourth day (0.0 points vs. 0.5 points, p < 0.05) 
after UCO. Under the influence of CD «Picamilon» reduction of neurological deficit compared 
with CP was observed on the first, third and fourth days, but these differences were insignificant.
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Table 2 
The effect of KGM-5 on the severity of neurological symptoms in rats with the ACVA model, Ме (LQ; UQ)
Groups of animals n
Neurological deficit according to McGraw Stroke-Index Scale, points
24 h 48 h 72 h 96 h
Intact control (IC) 6 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0)
Pseudo-operated animals (POA) 8 0 (0; 0,5)** 0 (0; 0)** 0 (0; 0)** 0 (0; 0)
Control pathology (CP) 8 1.25 (0.75; 1.5)* 1.0 (0.5; 1)* 1(0; 1)* 0,5 (0; 1)
ACVA+KGM-5 (30 mg/kg, ip) 12 0.5 (0; 1)*/**/# 0 (0; 1) 0 (0; 0)** 0 (0;.0)**
ACVA+CD «Picamilon» (17 mg/kg, ip) 10 1.0 (0.5; 1)*/# 1.0 (0.5; 1)*/# 0 (0; 0,5) 0 (0; 0)
р 0.0001 0.0021 0.0075 0.0037
Note: p is the level of statistical significance when comparing samples using ANOVA analysis of variance; * – statistical signifi-
cance compared with IС (Mann-Whitney test), p < 0.05; ** – statistical significance compared with СP (Mann-Whitney test), p < 0.05; 
# – statistical significance compared with POA (Mann-Whitney test), p < 0.05; n – number of animals
72 hours after ACVA simulation, the state of cognitive functions was assessed in an extrap-
olation escape test, which characterizes the ability of animals to find a way to get rid of an acute 
stressful situation [9]. Extrapolation escape test (EET) is used in psychopharmacology as a sensi-
tive method for studying cognitive functions in an acute stressful situation, which is the placement 
of animals in a cylinder of water. Latent diving period (LDP) or time before the task of deprivation 
was the studied parameter in this model. It was found (Table 3) that LDP in animals from the POA 
group was slightly increased compared to IC, but these differences were not significant (p > 0.05). 
Table 3
The effect of KGM-5 on the cognitive functions of rats in the extrapolation escape test 72 hours after ACVA 
simulation
Groups of animals n
Indexes
Latent diving period, s The number of animals that completed the task within 180 s/%
Intact control (IC) 6 108.7 ± 23.9 5/83.3
Pseudo-operated animals (POA) 8 159.1 ± 13.9* 3/37.5f
Control pathology (CP) 8 114.8 ± 13.6** 7/87.5
ACVA+KGM-5 (30 mg/kg, ip) 12 89.5 ± 15.3** 8/66.7
ACVA+CD «Picamilon» (17 mg/kg, ip) 10 95.4 ± 21.5** 7/70.0
р = 0.0425
Note: p is the level of statistical significance when comparing samples using ANOVA analysis of variance; * – statistical signifi-
cance compared with IС (Mann-Whitney test), p < 0.05; ** – statistical significance compared with СP (Mann-Whitney test), p < 0.05; 
f – statistical significance compared to IС (Fisher test), p < 0.05; n – number of animals
LDP in animals with ACVA model (group CP) was increased compared with LDP in an-
imals from group IC by 1.5 times (p < 0.05) and a significant decrease in the proportion of an-
imals that completed the task within 180 s (37.5 % against 83.3 % in IC group, p < 0.05, Fisher 
test), indicating the development of cognitive impairment as a result of ACVA caused by UCO. 
The compound KGM-5 contributed to a significant (p < 0.05) 1.8-fold reduction in LDP compared 
with CP, almost to the level of IC. The comparison drug «Picamilon» also contributed to a sig-
nificant (p < 0.05) 1.7-fold reduction in LDP compared with CP. Therefore, both agents studied 
improved cognitive function in rats after ACVA modeling.
4. Discussion
Under ACVA, a number of pathological disorders, such as decreased cerebral blood flow (ener-
gy deficit), glutamate «excitotoxicity», intracellular accumulation of calcium ions, activation of free 
radical processes («oxidative stress»), gene expression of early response, local inflammatory reac-
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tions, local inflammatory reactions, damage to the blood-brain barrier, necrosis, apoptosis and other 
forms of neuronal death always develop [5, 19]. Under ACVA, the weakening of GABA-ergic pro-
cesses is a significant link in the development of chronic disorders and, consequently, the subsequent 
depletion of neuronal structures of the brain and the development of cognitive impairment and neuro-
logical deficit [10, 11, 20]. Gamma-aminobutyric acid (GABA), which is a natural neurotransmitter, is 
a central link in the implementation of central inhibition processes through interactions with specific 
GABA receptors in various brain structures. This has a beneficial effect on neuronal energy, neuro-
dynamics, cerebral circulation, a combination of calming and mild psychostimulant action, which 
results in a positive effect on cerebral hemodynamic, cognitive and neurological functions [20].
It was found that GABA-ergic substances, in particular the drug «Picamilon», can improve 
blood supply to the brain, improve autoregulation of cerebral blood flow, inhibit the glutamate-cal-
cium cascade, prevent lipid peroxidation and increase the activity of antioxidant systems, pro-
vide inhibition of prevent destructive changes in neurons and improve neurological deficit [20]. 
These data make obvious the prospects for the development of effective neuroprotectors based on 
GABA-ergic substances, one of which is a new derivative of 4-aminobutanoic acid – a compound 
codenamed KGM-5, for which proven antiamnestic and antihypoxic activity [13].
In this experiment, the cerebroprotective effect of KGM-5 was assessed by an integral cri-
terion – animal survival (throughout the experiment), indicators of neurological deficits on the 
McGraw Stroke-Index Scale (24, 48, 72, 94 hours after ACVA modelling), the state of cognitive 
functions in extrapolation deprivation (EET) tests (72 hours after ACVA simulation).
It was found that the KGM-5 compound at a dose of 30 mg/kg as well as CD «Picamilon» 
contributed to some increase in survival of animals compared to CP, but these differences were 
insignificant. Under the influence of both studied agents, the survival of animals was significantly 
lower compared to POA (p < 0.05 according to Fisher’s test).
The KGM-5 compound significantly reduced the severity of neurological deficits, as evi-
denced by significant differences in this indicator on the first, third and fourth days after UCO 
compared with CP in contrast to CD «Picamilon», which was less influential.
In the EET test, it was found that both agents tested improved cognitive function in rats after 
ACVA modelling: the KGM-5 compound contributed to a significant (p < 0.05) 1.8-fold reduction 
in LDP compared to CP, almost to the level of IC, CD «Picamilon» also contributed to a signifi-
cant (p < 0.05) 1.7-fold reduction in LDP compared with CP.
Thus, the obtained results indicate the cerebroprotective activity of a new derivative of 
4-aminobutanoic acid of the KGM-5 compound in conditions of acute brain disorder. The severity 
of cerebroprotective activity of the new compound is not inferior to GABA-ergic comparison drug 
«Picamilon».
Study limitations. The reliability of data on the ability of KGM-5 to increase animal sur-
vival with the ACVA model is limited by the number of animals.
Prospects for further researches. The presence of cerebrotectory activity in KGM-5 com-
pounds under ACVA actualizes the feasibility of studying its effectiveness in other conditions, in 
particular in traumatic brain injury.
5. Conclusions
In conditions of acute cerebrovascular accident in rats, the ability of a new derivative of 
4-aminobutanoic acid to reduce the severity of neurological deficits and improve cognitive function 
in the test of extrapolation deprivation, indicating cerebroprotective activity.
The severity of cerebroprotective activity of the new compound is not inferior to GABA- 
ergic comparison drug «Picamilon».
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